Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Br J Surg ; 110(11): 1490-1501, 2023 Oct 10.
Artigo em Inglês | MEDLINE | ID: mdl-37478362

RESUMO

BACKGROUND: Colon cancer in young patients is often associated with hereditary syndromes; however, in early-onset rectal cancer, mutations of these genes are rarely observed. The aim of this study was to analyse the features of the local immune microenvironment and the mutational pattern in early-onset rectal cancer. METHODS: Commonly mutated genes were analysed within a rectal cancer series from the University Hospital of Padova. Mutation frequency and immune gene expression in a cohort from The Cancer Genome Atlas ('TCGA') were compared and immune-cell infiltration levels in the healthy rectal mucosa adjacent to rectal cancers were evaluated in the IMMUNOlogical microenvironment in REctal AdenoCarcinoma Treatment 1 and 2 ('IMMUNOREACT') series. RESULTS: In the authors' series, the mutation frequency of BRAF, KRAS, and NRAS, as well as microsatellite instability frequency, were not different between early- and late-onset rectal cancer. In The Cancer Genome Atlas series, among the genes with the most considerable difference in mutation frequency between young and older patients, seven genes are involved in the immune response and CD69, CD3, and CD8ß expression was lower in early-onset rectal cancer. In the IMMUNOlogical microenvironment in REctal AdenoCarcinoma Treatment 1 and 2 series, young patients had a lower rate of CD4+ T cells, but higher T regulator infiltration in the rectal mucosa. CONCLUSION: Early-onset rectal cancer is rarely associated with common hereditary syndromes. The tumour microenvironment is characterized by a high frequency of mutations impairing the local immune surveillance mechanisms and low expression of immune editing-related genes. A constitutively low number of CD4 T cells associated with a high number of T regulators indicates an imbalance in the immune surveillance mechanisms.

2.
Int J Colorectal Dis ; 28(2): 261-6, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22932907

RESUMO

PURPOSE: Radiation proctitis is a known complication following radiation therapy for pelvic malignancy. The majority of cases are treated nonsurgically. Rectal instillation of formalin solution has been described as a successful treatment for chronic radiation-induced hemorrhagic proctitis resistant to medical treatment. We present our results in patients undergoing treatment with application of 4 % formalin for radiation-induced injury to the rectum. METHODS: All patients were treated under anesthesia by direct application of 4 % formalin solution to the affected rectal areas. Patient gender, initial malignancy, grade of proctitis, need for blood transfusion, previous therapy, number of applications and response to treatment with formalin, complications, and length of follow-up were reviewed. RESULTS: A total of 15 patients with a mean age of 68.9 (range, 48-77) years were followed for 31.3 (range, 18-51) months. The mean interval from the conclusion of radiotherapy and the onset of symptoms was 6.9 months. The mean duration of hemorrhagic proctitis before formalin application was 7.9 months. Ten patients had only one formalin application and five patients required a second application because of the persistent bleeding. Thirteen patients (87 %) had complete cessation of bleeding. No complications related to the formalin treatment were observed. CONCLUSIONS: According to a revision of the literature and our experience, despite the small number of patients in our trial, we can state that the application of 4 % formalin solution is an effective, safe, and well-tolerated treatment for chronic radiation-induced hemorrhagic proctitis with minimal discomfort and no severe complications.


Assuntos
Formaldeído/uso terapêutico , Proctite/tratamento farmacológico , Lesões por Radiação/tratamento farmacológico , Idoso , Doença Crônica , Demografia , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade
3.
Ann Ital Chir ; 79(1): 29-36, 2008.
Artigo em Inglês | MEDLINE | ID: mdl-18572736

RESUMO

BACKGROUND: Morgagni's hernia is a rare and congenital type of diaphragmatic hernia. The majority of these are asymptomatic and diagnosed incidentally during evaluation or treatment for other conditions. When diagnosis is made surgery is mandatory. The Authors report the laparoscopic repair of small Morgagni hernia, followed by review of the literature. MATERIALS AND METHODS: A case of 55-year-old woman complaining a sensation of tightness in her chest, but especially an oppressive epigastric pain with episodes of fainting fit and breathless is described. The definitive diagnosis was confirmed by laparoscopy. The hernia was repaired laparoscopically using a mesh fixed by hernia stapler after excision of the sac. RESULTS: In the postoperative patients has presented an episode of heart condition due to pericarditis treated pharmacologically. The patient was discharged on the seventh postoperative day symptom-free. CONCLUSIONS: Laparoscopic technique must be considered as a first line approach for the treatment of Morgagni hernia, easy and safe by carry out. We recommend do not excise hernia sac, even if small, and particular cure in the use of the mesh fixed by metal staples.


Assuntos
Hérnia Diafragmática/diagnóstico , Laparoscopia , Feminino , Humanos , Pessoa de Meia-Idade
4.
Ann Ital Chir ; 76(4): 357-64; discussion 364-5, 2005.
Artigo em Italiano | MEDLINE | ID: mdl-16550873

RESUMO

AIM OF THE STUDY: The Authors report on two cases of small bowel stromal tumours and underline more recent findings regard to histogenesis, etiopathogenesis and classification as well examine the problems related to diagnosis, surgical management and prognosis of these pathology. CONCLUSIONS: At present, surgical treatment is the best therapy even in patients with local relapse and/or metastasis. Whereas in unresectable patients a new therapeutic possibility is given to the use of Imatinib mesylate, nevertheless is still to prove its effectiveness in regard to survival or as adyuvant treatment in resectable patients with high risk of relapse.


Assuntos
Tumores do Estroma Gastrointestinal , Neoplasias do Íleo , Feminino , Seguimentos , Tumores do Estroma Gastrointestinal/diagnóstico , Tumores do Estroma Gastrointestinal/diagnóstico por imagem , Tumores do Estroma Gastrointestinal/patologia , Tumores do Estroma Gastrointestinal/cirurgia , Humanos , Neoplasias do Íleo/diagnóstico , Neoplasias do Íleo/diagnóstico por imagem , Neoplasias do Íleo/patologia , Neoplasias do Íleo/cirurgia , Íleo/patologia , Pessoa de Meia-Idade , Radiografia Abdominal , Fatores de Tempo , Tomografia Computadorizada por Raios X
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA